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Objectives: To develop a measure that is based on the Inter-
national Classification of Functioning, Disability and Health 
(ICF) and reflects the prevalence and severity of disabilities 
related to neuromuscular disorders, and to evaluate the psy-
chometric properties of this measure.
Methods: A preliminary questionnaire was developed, based 
on the categories of the ICF Core Set for Neuromuscular 
Diseases. Next a cross-sectional postal survey was carried 
out among 702 patients (70% response rate) diagnosed with 
a neuromuscular disease. Finally, psychometric properties 
were examined.
Results: The preliminary Neuromuscular Disease Impact 
Profile (NMDIP) consisted of 45 items. Factor analysis 
showed that the NMDIP comprised domains representing 
3 ICF-components: 5 factors in the Body Functions com-
ponent, 2 factors in the Activities component, and 1 factor 
in the Participation component. Scales showed moderate 
to good internal consistency (α = 0.63–0.92) and mean in-
ter-item correlation coefficients (0.38–0.77). Convergent and 
discriminant validity analysis indicated that the NMDIP 
measures the impact of neuromuscular disease on physical, 
mental, and social functioning. The NMDIP discriminates 
between groups who differ in extent of limitations. 
Conclusion: The NMDIP is an ICF-based measure that re-
flects neuromuscular disease-related disabilities. It consists 
of 36 items divided over 8 scales with satisfactory psycho-
metric properties and 4 single items. 
Key words: neuromuscular disease; health measure; Internation-
al Classification of Functioning Disability and Health; psycho-
metric properties.
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INTRODUCTION
Neuromuscular diseases (NMD) may be acquired or hereditary. 
Causes are dysfunction of the anterior horn cell or sensory 
ganglion cell (neuronopathy), peripheral nerve (neuropathy), 
neuromuscular junction (myasthenia), or muscle (myopathy) 
(1). Common symptoms of neuromuscular diseases include 
muscle weakness, impairment in muscle endurance, involun-
tary muscle activity (stiffness, myotonia, cramp, and fascicu-
lation), sensory loss, autonomic dysfunction and impairment 
in control of voluntary movements. Sensations of pain and 
fatigue are common consequences of these muscle and nerve 
disturbances (2, 3). These symptoms have a profound impact 
on daily activities and participation in life situations (4, 5). 
In clinical practice and research there is a need for reliable 
and validated assessment tools as well as outcome measures 
that cover the broad range of health problems in neuromuscular 
patients (6).
Over the last 2 decades many health measurement instru-
ments have been developed for use both in clinical practice and 
in research. As a result, there are generic health-related quality 
of life (HRQoL) instruments with a broad scope, for example, 
the Medical Outcome study Short Form Questionnaire (SF-36) 
(7). An example of a disease-specific HRQoL instrument with 
a broad scope is the Amyotrophic Lateral Sclerosis Assessment 
Questionnaire (ALSAQ-40) (8). In addition, there are generic 
and domain-specific measures to assess limitations in daily 
living, for example the Groningen Activity Restriction Scale 
(GARS) (9), or to assess participation in life situations, for 
example, the Impact on Participation and Autonomy Ques-
tionnaire (IPAQ) (10). 
The International Classification of Functioning, Disability, 
and Health (ICF) is a classification developed by the World 
Health Organization (WHO) and aims at providing a unified 
and standardized language for describing and classifying 
health domains and health-related states, and hence providing 
a common framework for the development of health outcome 
measures (11, 12). 
The ICF comprises 4 key components. The first component, 
Body Functions and Structures, refers to functions of body 
systems, and to anatomic parts. The second component, Ac-
tivities, refers to “task or action execution by the individual”. 
The third component, Participation, refers to “involvement in 
life situations”. The Environmental Factors that interact with 
these 3 components, are described in the fourth component 
of the ICF (11).
In the model of functioning that underlies the ICF classifi-
cation system, the components body functions and structures, 
activities and participation are summarized under the concepts 
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“functioning” and “disability”. These are associated both with 
health status and with personal and environmental factors. 
Functioning is an umbrella term encompassing all body func-
tions, activities and participation. Similarly, disability is an 
umbrella term for impairments in body functions, limitations 
in activities and restrictions in participation (11). ICF Core 
Sets have been the first approach to providing ICF-based in-
struments for clinical practice and research (13). An example 
of such ICF-based measures is the Multiple Sclerosis Impact 
Profile (MSIP) (14). This measurement instrument has shown 
to be a feasible assessment tool in practice and psychometri-
cally sound measures in research. To the best of our knowledge 
there is no broad ICF-based health measure covering all 600 
NMDs. Therefore the aim of this study was to develop an 
ICF-based measure, the Neuromuscular Disease Impact Profile 
(NMDIP), with the intention of reflecting the prevalence and 
severity of a broad range of disabilities related to neuro-
muscular diseases, using the ICF features such as ICF termi-
nology and ICF qualifiers and to evaluate the psychometric 
properties of this new measurement instrument.
METHODS
Sample and procedures
A cross-sectional postal survey was conducted among patients diag-
nosed with a neuromuscular disease and registered at the Department 
of Neurology of the University Medical Center Groningen, the Nether-
lands. Criteria for inclusion were: diagnosed with a neuromuscular 
disease, aged 18 years or older, and able to read and write in Dutch. 
In total 1,003 eligible patients were selected from the hospital patient 
record system with the aim of representing the 4 major neuromuscular 
disease (NMD) groups defined by Rowland: motor neurone disorders, 
muscle disorders, junction disorders and, peripheral nerve disorders (15). 
To prevent any inappropriate sending of the questionnaire, we cross-
checked for deceased patients using the national population register. 
Patients received information about the study and were invited to 
participate. Respondents completed the preliminary NMDIP, generic 
and domain-specific questionnaires, along with some demographic 
and disease-specific questions. Reminders were sent out after 2 weeks. 
Ethical approval was obtained from the local ethics committee. 
Reference: METc 2009.310.
Preliminary Neuromuscular Disease Impact Profile
The preliminary NMDIP was developed as a disease-specific and ICF-
based measure to assess disability among patients with an NMD. We 
used the 69 ICF categories of the NMD-Core Set (3). These categories 
are divided over the 4 ICF components. Selected categories were 
operationalized in order to estimate the patient’s objectified opinion 
(impairment in body functions, limitations in activities or restrictions 
in participation) of the incidence and severity of a disability, and to 
estimate the support from relevant environmental factors. Furthermore, 
ICF terminology for “disabilities” was applied, ICF item labels were 
used when formulating the subject of the question (e.g. “urination” 
functions instead of “bladder” functions), and ICF codes (e.g. b280 
or p920) were documented for each question (14). Illustrative exam-
ples were annexed (using fourth-level ICF-items) to some questions 
to ensure an adequate response. To record the presence and severity 
of a problem in functioning, we applied response scales with scor-
ing options specified for each ICF component, based on “qualifiers” 
proposed by the ICF (14). 
The preliminary questionnaire was reviewed by patients, clinicians, 
nurse specialists, experts on the ICF and methodologists (n = 24) for 
clarity, comprehensiveness, redundancy and patient burden. A modified 
questionnaire was pre-tested in a random sample of 3 clinicians and 
50 patients who were not involved in the first appraisal of the ques-
tionnaire. Unclear or ambiguous items and instructions were identified 
and some modifications of the questionnaire were made. 
Finally, the preliminary NMDIP reflects an objectified view of the 
prevalence and severity of NMD-related disabilities and consists of 
45 items representing the 4 ICF components. 
Measurement instruments
For evaluating the psychometric properties of the NMDIP, 2 generic 
and 2 domain-specific measures were used.
The SF-36 is a broad and generic HRQoL measure that consists of 36 
items divided over 8 domains (7). For each domain, item scores were 
transformed to a scale that ranges from 0 (worst health) to 100 (best 
health). In a previous study among Dutch multiple sclerosis patients 
the SF-36 domains showed satisfactory levels of internal consistency: 
Cronbach’s alpha ranged between 0.74 and 0.96 (14).
The World Health Organization Quality Of Life (abbreviation 
version) (WHOQOL-bREF) is a broad and generic measure of global 
QoL (16), and consists of 26 items divided over 4 domains. For each 
domain, item scores were transformed to a scale that ranges from 0 
(worst health) to 20 (best health). In a previous study among Dutch 
multiple sclerosis patients the WHOQOL-bREF showed good levels 
of internal consistency: Cronbach’s alpha ranged between 0.80 and 
0.81 (14).
The GARS is a domain-specific instrument to measure limitation, 
and consists of 18 items divided over 2 domains (9). A 4-category 
response format is used, ranging from 1 (no problem in performing 
without help) to 4 (impossible to perform). Scores are summed for 
each subscale. The GARS showed strong levels of internal consisten-
cy: Cronbach’s alpha ranged from 0.95 to 0.97 in a study in a Dutch 
sample of multiple sclerosis patients (14).
The IPAQ is a domain-specific questionnaire focusing on person-per-
ceived participation and autonomy (10, 17). The instrument assesses 
2 aspects of participation: perceived participation and the perceived 
problem. In this study we applied the perceived participation part 
that consists of 24 items divided over 5 domains. Items are scored on 
a 5-point rating scale with discrete responses, ranging from 1 (very 
good) to 5 (very poor). Scores are summed for each domain. In a 
previous study among Dutch multiple sclerosis patients, the IPAQ 
showed good levels of internal consistency: Cronbach’s alpha ranged 
from 0.86 to 0.94 (14).
Item reduction
Exploratory factor analysis with oblique rotation (Geomin) (20, 23) 
was used to examine whether the domains measured by the NMDIP 
represent the 4 ICF components. To improve the content validity the 
prevalence of each item was examined before entering items in the 
factor analysis. Items with a low prevalence (≤ 20%) were excluded 
from further analysis (18, 19). Factor analyses were performed using 
Mplus 6 software (20). Given the categorical nature of the variables, 
methods based on polychoric correlations and the robust-weighted least 
squares estimators (21) were used. Goodness-of-fit of the underlying 
factorial structure was measured by the root mean squared error of 
approximation (RMSEA, adequate if below 0.06) and the standardized 
root mean square residual (SRMR, adequate if below 0.08), the Com-
parative Fit Index and the Tucker-Lewis Index. For the latter 2 indices, 
it is recommended that values should be greater than 0.95 (22, 23). 
Items with factor loadings ≥ 0.40 were selected for scale construction.
Items that could not meet the criteria of scalability were taken into 
consideration for use as a single indicator. 
Missing items
The maximum number of missing items allowed to be replaced by the 
mean scale score was determined by a sufficient Cronbach’s alpha in 
relation to the number of scale items (19, 24). 
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Psychometric evaluation
The distribution of scale scores was evaluated by calculating the medi-
an, mean and standard deviation and observed score range. Proportion 
of patients with worst and best possible scores (floor and ceiling effect) 
were calculated. Proportions ≤ 20% were considered acceptable (18).
Internal consistency was examined with Cronbach’s alpha (25) and 
the mean inter-item correlation coefficient (MICC) for each scale (26, 
27). Alpha was considered sufficient if ≥ 0.70 (28, 29), and MICC if 
≥ 0.30 (26). 
To test whether NMDIP scales measure physical, psychological, 
social, and environmental domains of functioning, as they purport 
to measure, convergent and discriminant validity were assessed by 
examining the extent to which correlation values between NMDIP 
scales and concurrent measures were consistent with hypotheses (30, 
31). Regarding convergent validity, we hypothesized that the NMDIP 
scales would have a strong correlation (≥ 0.70) (32) with scales that 
cover the same domain in concurrent measures. For example, NMDIP 
scales for physical functions should correlate highly with the SF-36 
“Physical Functioning scale”. To support discriminant validity, we 
hypothesized that the NMDIP scales would correlate weakly (< 0.40) 
with scales measuring different domains in NMDIP or concurrent 
measures. For example, NMDIP scales for physical function would 
correlate weakly with mental or emotional scales of the SF-36.
Regarding known-groups validity (30, 31), we hypothesized that the 
NMDIP scales should be able to discriminate between subgroups of 
respondents known to differ on relevant clinical characteristics. The 
level of limitations due to a neuromuscular disease was used to create 
relevant subgroups of respondents. Therefore, the generic question 
“Extent of limitations” was used. Respondents were asked to answer 
the question “To what extent are you limited due to a neuromuscular 
disease?” on an 11-point scale with a score range from 0 (not limited 
at all) to 10 (severely limited). Next, respondents were divided into 
2 groups: those with a “lower extent of limitations” (score 1–4), and 
those with a “higher extent of limitations” (score 5–10). 
Statistical analysis
Patient characteristics were analysed using descriptive statistics. Spear-
man’s correlation coefficient (rho) was used to examine convergent 
and discriminant validity. Known-groups validity was assessed using 
the independent Mann-Whitney U test. 
To estimate the magnitude of the difference in scores between 
subgroups of respondents, the non-parametric effect size (coefficient 
r) for unrelated samples was calculated for statistically significant 
group differences (alpha = 0.05) (33). Coefficient r is calculated by 
dividing the z statistic (obtained from the Mann-Whitney U test) by 
the root of the sample size (n). To interpret the non-parametric effect 
sizes using coefficient r. Cohen suggested the following thresholds for 
interpretation: an r of < 0.10 indicates a trivial effect, an r of ≥ 0.10 to 
< 0.24 a small effect, an r of ≥ 0.24 to < 0.37 a moderate effect, and an r 
≥ 0.37 a large effect. An r ≥ 0.10 reflects a clinically relevant difference 
between groups (33, 34). IbM SPSS statistics version 20 was used.
RESULTS
Patient characteristics
In total 702 participants (70% response rate) completed the 
questionnaires. Demographics and disease-specific charac-
teristics are described in Table I. Mean age was 59 years (SD 
16, range 19–92 years), while slightly more than half of the 
patients were younger than 65 years. Mean number of “years 
since diagnosis” was 12 (SD 11, range 0–65 years). Approxi-
mately 30% of the patients were retired due to a neuromuscular 
disease. The motor neurone disorder subgroup was a relatively 
small sample compared with the other neuromuscular disease 
subgroups according to Rowland’s classification (15).
Non-respondents did not differ from respondents in terms of 
gender, but were significantly younger (mean 53, SD 19 years) 
than respondents (mean 59, SD 16 years). 
Content validity
Nine of the original 45 items showed a low prevalence (≤ 20%) 
and were not entered in the factor analysis. These items were 
from the component “Activities” (“a350 Conversation”, 
“a360 Using communication devices and techniques”, and 
“a465 Moving around using equipment”), the component 
“Participation” (p510–p540 items concerning “Personal 
care”, “p360 Communication devices and techniques, “p630 
Eating and drinking”, “p610 Acquiring a place to live” and 
“p850 Remunerative employment”), and from the component 
“Environmental Factors” (“e340 Personal care providers and 
personal assistants”). 
Item reduction
The EFA models showed a (very) good fit for the 5-factor 
model for the body Functions component, the 2-factor model 
for the Activities component, and the 1-factor model for the 
Participation component. Comparative Fit Index and Tucker-
Lewis Index values were above 0.95, SRMR values were below 
0.08 as recommended. The RMSEA values were below 0.06 for 
the body Functions component and Participation component, 
while the value for the Activities component was slightly higher 
(0.069), but still acceptable. For the Environmental Factors 





Age, years, mean (SD) [range] 59 (16) [19–92]
years since diagnosis, mean (SD) [range] 12 (11) [0–65]
Relationship status, n (%)
Relationship (married/partnership) 498 (71)
Single (unmarried/widowed/divorced) 186 (27)
Educational level, n (%)
Primary school/vocational training 235 (33)
Secondary school/vocational training 270 (38)
Higher education/vocational training 161 (23)
University 28 (4)
Employment status (more answers possible), n (%)
Enrolled in a training or study course 36 (5)
Employment (part-time or full-time) 173 (25)
voluntary work (part-time or full-time) 42 (6)
(Partially) retired due to NMD 213 (30)
Housewife/househusband 171 (24)
Retired due to age 244 (35)
NMD category, n (%)
Motor neurone disorder 43 (6)
Muscle disorder 154 (22)
Junction disorder 234 (33)
Peripheral nerve disorder 271 (39)
NMD: neuromuscular disease; SD: standard deviation.
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component no satisfying fit was found. Factor analysis reduced 
the remaining 36 items of the initial NMDIP to 32 items:
• Five factors within the body Functions component included 
15 items (Table II). Interpretation of item content, using the 
ICF first- and second-level category labels led to the fol-
lowing scale labels: “Muscle Functions” (MuF), “Movement 
Functions” (MoF), “Swallowing and Speech Functions” 
(SSF), “Excretion and Reproductive Functions” (ERF), and 
“Mental Functions and Pain” (MFP). 
• Two factors within the Activities component included 
14 items (Table III). These factors were given the labels, 
“Activities of Moving around”(AMA) and “Self-care and 
Domestic Activities” (SDA). One factor within the Partici-
pation component included 3 items (Table Iv). This factor 
was labelled “Participation in Life Situations” (PLS).
Finally, the body Functions component items “Seeing 
functions” and the Environmental Factor component items 
“Immediate family”, “Social security services”, and “Health 
services” with a sufficient prevalence and clinical relevance 
were added to the questionnaire as single items.
Scale features are shown in Table v. Internal consistency for 
7 NMDIP scales for the total sample was good and moderate 
for 1 scale. Cronbach’s alpha ranged from 0.63 to 0.92 and 
mean inter-item correlation coefficient ranged from 0.38 to 
0.77. Four scales showed a high floor effect.
The NMDIP scales within the NMD groups showed accept-
able to good internal consistency. (Table vI). For some scales 
the Cronbach’s alpha was weak, but this was compensated by 
a sufficient mean inter-item correlation coefficient, except for 
the “Swallowing and Speech Functions” scale in the peripheral 
nerve disorder group and the “Excretion and Reproductive 
Functions” scale in the muscle disorder group. 
Table Iv. Factor analysis with Participation components (n = 702) 
Factor 1




p910/p920 Recreation and leisure 0.903
bold figures are sufficient factorloadings selected for scale construction.
Table III. Factor analysis with Activities component categories (n = 702) 
Factor 1 Factor 2
Activities of Moving around (AMA)
Limitations in…
a410 Changing body position 0.860 0.005
a415 Maintaining body position 0.639 0.270
a420 Transferring oneself 0.711 0.251
a450 Walking 0.952 –0.035
a470 Using transportation 0.589 0.330
a920 Recreation and leisure 0.411 0.354
Self-care and Domestic Activities (SDA)
Limitations in…
a440 Fine hand use –0.003 0.758
a445 Hand and arm use –0.102 0.894
a510 Washing oneself 0.272 0.709
a520 Caring for body parts –0.007 0.904
a530 Toileting 0.335 0.585
a540 Dressing 0.200 0.754
a630 Preparing meals 0.057 0.863
a640 Doing housework 0.398 0.458
bold figures are sufficient factorloadings selected for scale construction.
Table II. Factor analysis with Body Functions component categories (n = 702) 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5
Muscle Functions (MuF) 
Impairment in…
b730 Muscle power functions 0.612 0.473 0.032 0.015 –0.054
b740 Muscle endurance functions 0.677 0.329 –0.003 –0.020 0.195
Movement Functions (MoF)
Impairment in…
b760 Control of voluntary movements functions 0.009 0.777 –0.100 0.023 –0.038
b765 Involuntary movements functions –0.315 0.849 0.106 –0.022 0.044
b780 Sensation related to muscles and movement functions 0.045 0.590 –0.041 0.053 0.198
Swallowing and speech functions (SSF)
Impairment in…
b320 Speech functions 0.024 0.144 0.842 0.008 –0.013
b5105 Swallowing functions 0.246 –0.035 0.687 0.053 0.054
Excretion and reproductive Functions (ERF)
Impairment in…
b525 Defecation functions 0.022 –0.030 –0.002 0.656 0.168
b620 Urination functions –0.052 0.028 0.036 0.785 –0.032
b640 Sexual functions 0.046 0.281 0.026 0.426 0.043
Mental Functions and Pain (MFP)
Impairment in…
b134 Sleep functions –0.028 –0.008 –0.055 0.091 0.680
b1300 Fatigue 0.460 0.019 0.062 0.011 0.593
b152 Emotional functions –0.020 –0.014 0.100 –0.148 0.725
b160 Thought functions –0.230 0.040 0.259 0.023 0.539
b280 Sensation of pain 0.078 0.267 –0.238 0.040 0.527
bold figures are sufficient factorloadings selected for scale construction.
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The final version of the NMDIP consists of 36 items divided 
over 8 scales and 4 single items (see Appendix I).
Psychometric testing
Table vII provides evidence of convergent and discriminant 
validity for the NMDIP scales, reflecting the impact of a 
neuromuscular disease on physical, psychological, and social 
aspects of functioning. The predictions were consistent with 
the direction, magnitude, and patterns of correlations. 
Convergent validity was supported by a strong correlation 
between the NMDIP “Muscle Functions” scale and the SF-36 
“Physical Functioning” scale, and a strong correlation be-
tween the NMDIP “Lower Extremity Activities” and “Upper 
Extremity Activities” scales, and the GARS “Activities of 
Daily Living” and “Instrumental Activities of Daily Living” 
scales. The NMDIP “Participation in Life Situations” scale 
was moderately correlated with the IPAQ participation scales. 
Discriminant validity was supported by weak correlation 
values found, for example, between the NMDIP “Mental 
Functions and Pain” scale and the SF-36 “Physical Function-
ing” scale, and the GARS “Activities of Daily Living” and 
“Instrumental Activities of Daily Living” scales. Similarly, 
the NMDIP “Muscle Functions” scale correlated weakly with 
the SF-36 “Mental Health and “Role Emotional” scales, and 
the NMDIP “Participation in Life Situations” scale correlated 
weakly with the SF-36 “Mental Health” scale. 
Evidence of known-groups validity was obtained for all 
NMDIP scales by statistically significant group differences and 
clinically relevant effect sizes (Table vIII). Patients classified 
as having a higher extent of limitation had statistically signif-
icant higher scores on all NMDIP scales compared with those 
classified as having a lower extent of limitation. Effect sizes 
were moderate for 2 scales, and large for 6 scales.
DISCUSSION
The objective of this study was to develop a psychometrically 
sound ICF-based measure for estimating the prevalence and 
severity of a broad range of disabilities related to neuromus-
cular diseases using ICF features such as ICF terminology 
and ICF qualifiers.
The results provide evidence to support the validity and 
reliability of the final version of the Neuromuscular Disease 
Impact Profile (NMDIP) as an instrument to measure the 
prevalence and severity of a broad spectrum of consequences 
of a neuromuscular disease including disabilities in body Func-
















% Median Mean SD Alpha MICC
NMDIP scales
Muscle Functions 658 2 0–8 0–8 8 3 4 3.4 1.9 0.87 0.77
Movement Functions 594 3 0–12 0–12 18 0 2 2.4 2.1 0.72 0.47
Swallowing and Speech Functions 669 2 0–8 0–6 59 1 0 0.7 1.1 0.69 0.53
Excretion and Reproductive Functions 509 3 0–12 0–12 27 0 1 1.8 3.1 0.63 0.38
Mental Functions and Pain 597 5 0–20 0–16 7 0 4 1.8 1.8 0.80 0.59
Activities of Moving Around 702 6 0–18 0–18 18 2 4 5.1 4.8 0.90 0.62
Self-care and Domestic Activities 701 8 0–24 0–24 28 1 2 4.7 6.0 0.92 0.59
Participation in Life Situations 695 3 0–12 0–12 49 0 1 1.7 2.4 0.72 0.47
NMDIP single item
Seeing functions 666 1 0–4 0–4 0 0.68 0.88
Immediate family 697 1 0–2 0–2 0 0.51 0.73
Social security services 268 1 0–2 0–2 1 0.74 0.77
Health services 693 1 0–2 0–2 0 0.66 0.75
MICC: mean inter-item correlation coefficient; SD: standard deviation.
Table vI. Internal consistency (Cronbach’s alpha) and the mean inter-item correlation coefficient (MICC) of the Neuromuscular Disease Impact Profile 









Alpha MICC Alpha MICC Alpha MICC Alpha MICC
Muscle functions 0.86 0.77 0.79 0.67 0.87 0.78 0.86 0.76
Movement functions 0.72 0.48 0.72 0.48 0.67 0.42 0.67 0.41
Swallowing and speech functions 0.82 0.72 0.74 0.59 0.63 0.47 0.42 0.27
Excretion and reproductive functions 0.71 0.47 0.54 0.30 0.63 0.36 0.68 0.45
Mental functions and pain 0.69 0.34 0.77 0.40 0.73 0.36 0.72 0.33
Activities of moving around 0.90 0.62 0.90 0.60 0.85 0.50 0.90 0.59
Self-care and domestic activities 0.95 0.69 0.93 0.63 0.83 0.43 0.88 0.47
Participation in life situations 0.80 0.57 0.74 0.49 0.67 0.40 0.67 0.41
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tions, Activities and Participation, and lack of support from 
Environmental Factors. The NMDIP can be used as a clinical 
and research instrument for the assessment of the impact of a 
neuromuscular disease.
The original 45 items in the preliminary NMDIP could be 
reduced to 36 items: 32 items covering 8 domains representing 
3 ICF-components, and 4 clinically relevant items (1 body 
Functions item and 3 Environmental Factors items), which 
were applied as single items in the questionnaire (see final 
version in Appendix I). 
Although the NMDIP used the same items as the initial MSIP 
(14), results of the factor analysis showed some differences 
compared with the final MSIP scales. For example, the MSIP 
“Muscle and Movement functions” 4-item scale is represented 
in the NMDIP in 2 separate and recognizable scales “Muscle 
functions” with 2 items and “Movement functions”, also with 2 
Table vII. Results of convergent and divergent validity analyses of the Neuromuscular Disease Impact Profile (NMDIP) scales (n = 702)
NMDIP
body functions Activities Participation
MuF MoF SSF ERF MFP AMA SDA PLS Alpha
NMDIP
Muscle Functions (MuF) 1 0.87
Movement Functions (MoF) 0.57 1 0.72
Swallowing and Speech Functions (SSF) 0.26 0.23 1 0.69
Excretion and Reproductive Functions (ERF) 0.35 0.43 0.31 1 0.63
Mental Functions and Pain (MFP) 0.49 0.59 0.34 0.48 1 0.80
Activities of Moving around (AMA) 0.72 0.58 0.23 0.41 0.48 1 0.90
Self-care and Domestic Activities (SDA) 0.63 0.52 0.31 0.45 0.51 0.79 1 0.92
Participation in Life Situations (PLS) 0.54 0.46 0.26 0.38 0.53 0.68 0.61 1 0.72
SF-36
Physical functioning –0.71 –0.52 –0.23 –0.40 –0.47 –0.85 –0.77 –0.61 0.94
Role physical –0.43 –0.42 –0.26 –0.37 –0.52 –0.43 –0.45 –0.40 0.88
bodily pain –0.38 –0.51 –0.17 –0.32 –0.65 –0.42 –0.40 –0.38 0.91
General health –0.49 –0.49 –0.32 –0.44 –0.60 –0.49 –0.48 –0.46 0.78
Mental health –0.21 –0.33 –0.18 –0.18 –0.53 –0.21 –0.25 –0.32 0.83
Role emotional –0.18 –0.30 –0.20 –0.21 –0.39 –0.23 –0.26 –0.25 0.87
Social functioning –0.44 –0.46 –0.29 –0.40 –0.63 –0.46 –0.46 –0.51 0.77
vitality –0.41 –0.42 –0.34 –0.33 –0.68 –0.35 –0.39 –0.39 0.81
WHOQOL-bREF
Physical health and autonomy –0.29 –0.30 –0.22 –0.29 –0.49 –0.29 –0.29 –0.33 0.84
Psychological health –0.25 –0.33 –0.25 –0.23 –0.43 –0.29 –0.30 –0.35 0.80
Social relation –0.23 –0.22 –0.14 –0.40 –0.37 –0.26 –0.25 –0.33 0.60
Environment –0.34 –0.39 –0.24 –0.27 –0.51 –0.41 –0.39 –0.46 0.82
GARS
Activities of daily living 0.64 0.54 0.26 0.45 0.44 0.81 0.81 0.62 0.95
Instrumental activities of daily living 0.67 0.49 0.30 0.44 0.49 0.78 0.84 0.62 0.93
IPAQ
Autonomy indoors 0.54 0.52 0.25 0.43 0.50 0.66 0.65 0.56 0.94
Family role 0.53 0.52 0.30 0.41 0.59 0.61 0.61 0.53 0.92
Autonomy outdoors 0.57 0.50 0.34 0.48 0.63 0.68 0.66 0.66 0.84
Social relations 0.34 0.35 0.32 0.41 0.53 0.41 0.45 0.48 0.85
NMDIP: n = 484–658; SF-36: n = 654–657; WHOQOL-bREF: n = 628–649; GARS: n = 655–658; IPAQ: n = 654–657.
bold correlations = expected convergent correlations. Italic correlations = expected discriminant correlations. 
MuF: Muscle functions; MoF: Movement functions; SSF: Swallowing and Speech functions; ERF: Excretion and Reproductive functions; MFP: 
Mental functions and Pain; AMA: “Activities of Moving around”; SDA: “Self-care and Domestic Activities”; PLS: Participation in life situations; 
GARS: Groningen Activity Restriction Scale; IPAQ: Impact on Participation and Autonomy Questionnaire.
Table vIII. Results of known-groups validity analyses of the Neuromuscular Disease Impact Profile scales (n = 702)








(Z-statistic) Effect size 
Muscle functions (MuF) 640 197.84 390.25 0.000 (–12.973) 0.51
Movement functions (MoF) 577 201.52 342.52 0.000 (–9.994) 0.42
Swallowing and speech functions (SSF) 651 273.86 359.14 0.000 (–6.445) 0.25
Excretion and reproductive functions (ERF) 495 198.34 279.74 0.000 (–6.374) 0.29
Mental functions and pain (MFP) 581 201.45 346.38 0.000 (–10.170) 0.42
Activities of moving around (AMA) 683 210.67 422.72 0.000 (–13.704) 0.52
Self-care and domestic activities (SDA) 682 227.58 411.25 0.000 (–11.956) 0.46
Participation in life situations (PLS) 677 239.81 400.46 0.000 (–11.110) 0.43
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items. Furthermore, the 3-item “Mental functions” MSIP scale 
appeared in the NMDIP as a 5-item version: new scale items 
were Fatigue and Pain. This can be explained by the fact that 
pain and fatigue are the direct result of (using) weakened mus-
cles, which is a common symptom in neuromuscular diseases. 
Unlike neuromuscular diseases fatigue in multiple sclerosis is 
most likely related to the process of inflammation, while pain 
originates from spasticity and/or neuropathy. Furthermore, 
scale construction also identified a construct that was not 
present in the MSIP: “Swallowing and Speech Functions”. 
This can be explained by the fact that some myopathies and 
the myasthenia’s tend to affect bulbar musculature. Finally, 
analysis showed no consistent factor for the Environmental 
Factors items.
Reliability of the NMDIP scales for the total sample was 
sufficient for 2 scales and good for 6 scales. The internal con-
sistency of the scales per separate NMD group was generally 
sufficient, except for the “Swallowing and Speech Functions” 
scale in the peripheral nerve disorder group and the “Excretion 
and Reproductive Functions” scale in the muscle disorder 
group. Some caution is advised in the interpretation of the 
results of these scales. Convergent and discriminant validity 
analysis indicated that the NMDIP measures the impact on 
physical, mental, and social functioning for people with a 
neuromuscular disease.
The correlation between the NMDIP “Participation in Life 
Situations” scale and the SF-36 “Physical Functioning” scale 
was unexpectedly higher. It is likely that the activity-related 
participation items in the NMDIP scale are responsible for this 
moderate correlation.
Known-groups validity was supported for the 8 NMDIP 
scales. Scales discriminated sufficiently between groups of 
patients with a neuromuscular disease that differed in extent 
of limitations. 
An important strength of this study is the large and broad 
group of participating patients with a neuromuscular disease, 
and the sound conceptual basis used in developing the NMDIP 
(3, 35).
A possible limitation of this study is the small sample size 
of the motor neurone disorder group, compared with the sam-
ple size of the 3 other NMD groups. However, in our opinion 
the disabilities in this group are sufficiently represented in 
the NMDIP because the basis of the NMDIP, the NMD ICF-
Core set, covers all items of the disease-specific Amyotrophic 
Lateral Sclerosis Assessment Questionnaire-40 (8). Another 
limitation could be the high floor effect of some scales that 
might affect the reliability of these scales (36). However, these 
floor effects match the course of the slowly progressive nature 
of most NMDs. This means that some disabilities appear years 
after onset, such as speech and swallowing functions or upper 
extremity activities.
Further research should focus on psychometric evaluation 
concerning stability and sensitivity to change of the NMDIP 
scales, and validation across other populations of neuromus-
cular disease patients in other cultures. It would also be inter-
esting to examine the differences in prevalence and severity 
of disabilities between the 4 major NMD groups, as defined by 
Rowland (15). Finally, it would be interesting to investigate 
the impact of the broad range of NMDIP-related disabilities 
on HRQoL of patients with neuromuscular diseases.
We considered the possibility of undertaking group invar-
iance testing; however, the sub-groups are relatively small 
and will affect the test of Differential Item Functioning. We 
therefore suggest further examination of the factor structure 
in a new sufficient sample.
In clinical practice, especially in multidisciplinary rehabilita-
tion teams, the NMDIP may contribute to better understanding 
the patients’ health problems when used as an assessment tool. 
Although positive results were found in the feasibility studies 
with the preliminary NMDIP and the MSIP, it is advisable to 
combine this application with research; for example, in order 
to investigate the effects on the healthcare plan when using 
the NMDIP. 
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APPENDIx I. Neuromuscular Disease Impact Profile (NMDIP). (Final 36-item version)
NMDIP body functioning questions
Scale Response options
0 = no, not at all
1 = yes, I have a slight impairment
2 = yes, I have a moderate impairment
3 = yes, I have a severe impairment
4 = yes, I have a complete impairment
MuF b1 Do you face loss of your muscle power functions? (b730)
MuF b2 Do you face loss of muscle endurance functions? (b740)
MoF b3 Do you face loss of control of voluntary movements? (b760)
MoF b4 Do you face involuntary movements? (e.g. tremors or tics) (b765)
MoF b5 Do you face muscle stiffness or muscle spasm? (b7800/b7801)
SSF b6 Do you face impairment in your speech functions? (b320) 
SSF b7 Do you face impairment in your swallowing functions? (b5105)
ERF b8 Do you face impairment in your defecation functions? (e.g. changes in frequency, constipation, incontinence) (b525)
ERF b9 Do you face impairment in your urination functions? (e.g. frequency of urination, incontinence, difficulties with 
urination) (b620)
ERF b10 Do you face limitations in sexual functions? (b640)
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APPENDIx I. Contd.
NMDIP body functioning questions
MFP b11 Do you face impairment in your sleep functions? (e.g. onset of sleep, the 
maintenance of sleep or the quality of sleep) (b134)
MFP b12 Do you experience fatigue? (b1300/b455) 
MFP b13 Do you face changes in your emotional functions? (e.g. fear, depression, 
happiness) (b152)
MFP b14 Do you face changes in your thought functions? (e.g. the ability to think 
logically, the ability to memorize, the ability to concentrate) (b160)
MFP b15 Do you experience sensation pain? (b280) 




1 = yes, but assistance devices and/or adaptations are not necessary
2 = yes, and assistance devices and/or adaptations are necessary
3 = yes, and assistance devices and/or adaptations and another person’s help are necessary
AMA a1 Do you face limitations in changing your body position? (e.g. moving from lying down to standing up or from standing to 
sitting) (a410)
AMA a2 Do you face limitations in maintaining your body position? (e.g. maintaining 
kneeling, standing, and sitting postures) (a415)
AMA a3 Do you face limitations in transferring yourself? (e.g. moving from a chair into bed; from a wheelchair into a car) (a420)
AMA a4 Do you face limitations in walking? (a450)
AMA a5 Do you face limitations in using transportation? (a470)
AMA a6 Do you face limitations in activities you would like to undertake for recreation and leisure? (a920)
SDA a7 Do you face limitations in your fine hand use? (e.g. picking up small objects; 
manipulating a keyboard) (a440)
SDA a8 Do you face limitations in your arm(s) and hand(s) use? (e.g. pulling or  pushing objects; turning or twisting knobs or 
handles; reaching for kitchen cupboard) (a445)
SDA a9 Do you face limitations in washing yourself? (a510)
SDA a10 Do you face limitations in caring for body parts? (e.g. brushing teeth, 
clipping your nails, combing your hair, shaving) (a520)
SDA a11 Do you face limitations in toileting? (a530)
SDA a12 Do you face limitations in dressing yourself? (a540)
SDA a13 Do you face limitations in preparing meals? (a630)




1 = yes, as a consequence I have some trouble with ….
2 = yes, as a consequence I have trouble with..
3 = yes, as a consequence I have a lot of trouble with …
4 = yes, as a consequence …. is (nearly) impossible
PLS p1 Are there obstacles in your environment that complicate your participation in community, recreation, and leisure? (e.g. 
accessibility of clubs or associations) (p910/p920)
PLS p2 Are there obstacles in your environment that complicate the maintenance of your relationships with your closest family, 
friends, or relatives? (e.g. the travel distance, the attitude of others) (p740–p760)
PLS p3 Are there obstacles in your environment that complicate your mobility inside or outside your home? (e.g. thresholds; 
curbs; absence of elevators) (p460/470)
NMDIP Environmental factors questions
Scale Response options
0 = yes, very supportive; 
1 = yes, somewhat supportive; 
2 = No, not supportive
Single 
Item e1 Is your relationship with your immediate family supportive for you? (e.g. partner, children, parents, brothers, sisters) 
(e310)
Single 
Item e2 Are the social security services supportive for you? (e.g. income support) (e570)
Single 
Item e3 Are the health services supportive for you? (e.g. medical and nursing care) (e580)
MuF: Muscle functions; MoF: Movement functions; SSF: Swallowing and Speech functions; ERF: Excretion and Reproductive functions; MFP: Mental 
functions and Pain; AMA: Activities of moving around; SDA: Self-care and domestic activities; PLS: Participation in life situations.
J Rehabil Med 47
